Colombia Médica

English version

Versión español

Check for updates

CrossMark

OPEN ACCESS

Citation: Boutrid N, Rahmoune H. **Fragile X primary ovarian insufficiency.** Colomb Méd (Cali), 2026; 57(1):e7005943 http://doi.org/10.25100/cm.v57i1.5943

Received: 23 Jan 2024
Revised: 28 Oct 2025
Accepted: 11 Mar 2026
Published: 30 Mar 2026

Copyright: © 2026 Universidad del Valle

Conflict of interest

The authors declare no conflicts of interest.

Funding

This study received no funding.

CRediT authorship contribution statement

H.R.: Conceptualization, Data curation, Writing - original draft, Writing - review & editing. **N.B.:** Conceptualization, Validation, Supervision, Writing - original draft, Writing - review & editing.

LETTERS TO THE EDITOR

Fragile X primary ovarian insufficiency

Insuficiencia ovárica primaria asociada al X frágil

Nada Boutrid,[1] Hakim Rahmoune[1]

1 Université Ferhat Abbas de Sétif, Faculty of Medicine, LMCVGN Research Laboratory, Algeria.

Dear Editor,

We read with great attention the review article on Fragile X Syndrome in children[1] recently published in Colombia Médica. However, we would emphasize the importance of recognizing and addressing the peculiar Fragile X-associated primary ovarian insufficiency.

Actually, premutation of the fragile X messenger ribonucleoprotein 1 (*FMR1*) gene is characterized by an expansion of the CGG trinucleotide repeats (55 to 200 CGGs) in the 5' untranslated region and increased levels of *FMR1* mRNA[2].

Clinically, premutation carriers may exhibit a wide range of symptoms and phenotypes: Fragile X-associated tremor/ataxia syndrome (FXTAS), fragile X-associated neuropsychiatric disorders (FXAND), and the peculiar fragile X-associated primary ovarian insufficiency (FXPOI): a condition that leads to infertility and early menopause in women, as well as irregular menstrual cycles, and is associated with elevated levels of follicle-stimulating hormone (FSH). Studies have also shown that between 12% and 28% of women who are fragile X premutation carriers have primary ovarian insufficiency, and, inversely, this condition is more common in women with the fragile X premutation: females with a premutation in their *FMR1* gene are at a higher risk for primary ovarian insufficiency, with approximately 20% of affected individuals developing this condition over their reproductive lifespan, compared to only 1% in the general population [3].

Genetically, females carrying premutation alleles in the 80-100 CGG range have the highest risk of ovarian dysfunction, estimated at 38% in this high-risk group. A recent, large cross-sectional study involving 1,668 females provided more individualized risk assessments for FXPOI by employing high-resolution repeat-size bins. This intra-population variability in risk has significant implications for genetic counseling, family planning, and future care for premutation carriers [4].

Interestingly, a nationwide register-based study found that genetic disorders and congenital malformations were strongly linked to premature ovarian insufficiency, especially when diagnosed at a young age, and early-onset POI could indicate an underlying genetic disorder like Fragile X syndrome, highlighting the need for further medical evaluations [5].

Clinicians should be aware of this peculiar association of Fragile X with POI to prevent delays in diagnosing and initiating appropriate hormone replacement therapy.

Declaration of AI use

During the preparation of this work, the authors used Perplexity in order to paraphrase and enhance the clarity of the text. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the publication's content.

Corresponding author

Hakim Rahmoune, e-mail: rahmoune hakim@gmail.com

References

1. Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, Rojas CA, Hagerman RJ. Fragile X Syndrome in children. Colomb Med (Cali) 2023;54(2):e4005089. doi: 10.25100/cm.v54i2.5089. [PubMed] [CrossRef] [Google Scholar]

2. Tassone F, Protic D, Allen EG, Archibald AD, Baud A, Brown TW, et al. Insight and recommendations for fragile X-premutation-associated conditions from the fifth international conference on FMR1 premutation. Cells. 2023;12(18):2330. doi: 10.3390/cells12182330. [PubMed] [CrossRef] [Google Scholar]

3. Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI) Menopause. 2016;23(9):993–999. doi: 10.1097/GME.0000000000000658. [PubMed] [CrossRef] [Google Scholar]

4. Allen EG, Charen K, Hipp HS, Shubeck L, Amin A, He W, et al. Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size. Genet Med. 2021;23(9):1648–1655. doi: 10.1038/s41436-021-01177-y. [PubMed] [CrossRef] [Google Scholar]

5. Silvén H, Savukoski SM, Pesonen P, Pukkala E, Ojaniemi M, Gissler M, et al. Association of genetic disorders and congenital malformations with premature ovarian insufficiency: a nationwide register-based study. Hum Reprod. 2023;38(6):1224–1230. doi: 10.1093/humrep/dead066. [PubMed] [CrossRef] [Google Scholar]

English version

Versión español

CrossMark

OPEN ACCESS

Citation: Saldarriaga W, Hagerman RJ. **Authors' response: Fragile X primary ovarian insufficiency.** Colomb Méd (Cali), 2026; 57(1):e7017436 http://doi.org/10.25100/cm.v57i1.7436

Copyright: © 2026 Universidad del Valle

Conflict of interest

The authors have no conflict of interest.

Corresponding author

Wilmar Saldarriaga, e-mail: wilmar.saldarriaga@correounivalle.edu.co

RESPONSE

Authors' response: Fragile X primary ovarian insufficiency

Respuesta de los autores: Insuficiencia ovárica primaria asociada al X frágil

Wilmar Saldarriaga[1,2] **Randi J. Hagerman**[3,4,5]

1 Universidad del Valle, Facultad de Salud, Escuela de Ciencias Básicas, Cali, Colombia. **2** Hospital Universitario del Valle "Evaristo García" E.S.E, Cali, Colombia. **3** University of California, Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, Sacramento, CA, USA. **4** UC Davis Medical Center, Sacramento, CA, USA. **5** University of California, Department of Pediatrics, Davis, CA, USA.

We are responding to the letter to the editor sent by distinguished readers of our article Fragile X in Children [1]. Their comments are based on the findings reported by Silvén *et al.* in 2023 [2], who found a significant association between genetic disease and/or congenital anomalies and early-onset primary ovarian insufficiency (POI). On this basis, the readers suggest that "Clinicians should be aware of this peculiar association of Fragile X with POI to prevent delays in diagnosing and initiating appropriate hormone replacement therapy."

POI is well documented in women carrying the premutation with alleles between 55 and 200 CGG triplets in the 5' untranslated region of the *FMR1* gene; in these women, POI is found in 20% and is named Fragile X-associated primary ovarian insufficiency (FXPOI), compared with only 1% of women in the general population [3,4].

Although Silvén *et al.* [2] report a significant association between genetic disease and/or congenital anomalies and early-onset POI, they do not refer specifically to cases of ovarian failure in women with the full mutation or with the premutation in the *FMR1* gene. In women with the full mutation, defined as more than 200 repeats of the CGG triplet, with or without intellectual disability, FXPOI has not been described. In the authors' experience, none of approximately 220 women with the full mutation had POI.

We would propose that in those adolescent or young women with genetic diseases and/or congenital anomalies in whom Müllerian anomalies, such as the absence of the uterus, and Turner syndrome have been ruled out, PCR with double or triple primers for the quantification of the triplets in the 5' untranslated region of the *FMR1* gene should be performed to identify whether they have a double genetic hit [5], the second hit being the *FMR1* premutation [6].

References

1. Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, Rojas CA, Hagerman RJ. Fragile X Syndrome in children. Colomb Med (Cali) 2023;54(2):e4005089. doi: 10.25100/cm.v54i2.5089. [PubMed] [CrossRef] [Google Scholar]

2. Silvén H, Savukoski SM, Pesonen P, Pukkala E, Ojaniemi M, Gissler M, et al. Association of genetic disorders and congenital malformations with premature ovarian insufficiency: a nationwide register-based study. Hum Reprod. 2023;38(6):1224–1230. doi: 10.1093/humrep/dead066. [PubMed] [CrossRef] [Google Scholar]

3. Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI) Menopause. 2016;23(9):993–999. doi: 10.1097/GME.0000000000000658. [PubMed] [CrossRef] [Google Scholar]

4. Allen EG, Charen K, Hipp HS, Shubeck L, Amin A, He W, et al. Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size. Genet Med. 2021;23(9):1648–1655. doi: 10.1038/s41436-021-01177-y. [PubMed] [CrossRef] [Google Scholar]

5. Saldarriaga W, Payán-Gómez C, González-Teshima LY, Rosa L, Tassone F, Hagerman RJ. Double genetic hit: fragile X syndrome and partial deletion of protein patched homolog 1 antisense as cause of severe autism spectrum disorder. J Dev Behav Pediatr. 2020;41(9):724–728. doi: 10.1097/DBP.0000000000000850. [PubMed] [CrossRef] [Google Scholar]

6. Lozano R, Hagerman RJ, Duyzend M, Budimirovic DB, Eichler EE, Tassone F. Genomic studies in fragile X premutation carriers. J Neurodev Disord. 2014;6(1):27. [PubMed] [Google Scholar]